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ABSTRACT 
  
 
Oxidative stress is the result of an imbalance in the cellular pro-/antioxidant homeostasis 
which leads to the overproduction of reactive oxygen species (ROS). Usually, oxidative 
stress leads to structural and functional disruption within the cells, which in turn may 
cause cell death through different mechanisms. The brain is very sensitive to oxidative 
damage because of its high oxygen consumption, and oxidative stress is known to be 
involved e.g. in neurodegenerative diseases such as Huntington’s disease (HD).  
 
X-linked Inhibitor of Apoptosis Protein (XIAP), one of the best-characterized apoptosis 
inhibitor proteins, is expressed both during development, and in the adult brain. 
Overexpression of XIAP is known to protect cells against various injuries and cell 
degeneration. XIAP can prevent cell death through various signalling cascades, e.g. by 
preventing caspases which are essential for apoptotic cell death. The function of XIAP in 
oxidative stress-related reactions is not that well-studied, which led us to examine it more 
closely. We found out that XIAP is able to reduce oxidative stress and cell death caused 
by ROS in vitro in neuron-like PC6.3-cells. We also noticed that XIAP increases the 
activation of transcription factor NFκB in these cells. Via NFκB, XIAP also increased 
two mitochondrial antioxidants: superoxide dismutase 2 (SOD2) and thioredoxin 2 
(TRX2), and the significance of NFκB in this effect was also shown by using fibroblast 
cell lines from NFκB p65-/- mice. Furthermore, we observed that XIAP enhances BDNF 
signalling through NFκB in E17 HC neurons. In the PC6.3-cell model of HD there was a 
correlation between the increased amount of ROS and the enhanced number of glutamine 
repeats. The protein levels of intracellular antioxidants and NFκB were decreased in cells 
expressing mutant huntingtin (htt) proteins compared to control cells. Last but not least, 
we observed that resveratrol (RSV) pre-treatment is able to reduce oxidative stress and 
cell death caused by ROS in PC6.3-cells. RSV also increased the amount of SOD2, 
TRX2 and XIAP, and the NFκB system may be involved in the increase of antioxidant 
proteins mediated by RSV.  
 
Altogether, these results bring us closer to understanding the role of XIAP in the control 
of oxidative stress and the function of XIAP in NFκB and BDNF signalling. In view of 
this, modulation of XIAP is an interesting possibility to consider in various therapies to 
reduce cell injuries caused by enhanced oxidative stress. RSV would also be a really 
interesting compound to examine as a drug candidate in disorders where oxidative stress 
is involved. However, studies to analyse its kinetics, actions and pharmacological and 
toxicological profiles are still lacking. 
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1. REVIEW OF THE LITERATURE 
 
1.1 General features of cell death  
 
Kerr and coworkers (Kerr et al., 1972) divided cell death types into two categories 
according to their morphological structures: apoptosis and necrosis. Studies within past 
few years have also represented a third mechanism for cell death called necroptosis 
(Degterev et al., 2005, Teng et al., 2005b).  
 
Apoptosis is an active, regulated cell death process and it is required during development 
and for homeostasis of an organ system. Activation of caspases (cysteine-aspartic acid 
proteases) has a leading role in apoptotic cell death, and some caspases are also required 
in the immune system. One of the primary contributors in tumour development and 
autoimmune diseases is deficiency of apoptosis, whereas unwanted apoptosis is occuring 
in ischemia and neurodegenerative diseases. Necrosis is a passive, pathological process 
and it is caused by extrinsic factors like infection or toxins. Necrosis is typically 
characterized by disruption of cell membranes and activation of the immune system.  
 
Recent reports have described a caspase-independent but programmed and active cell 
death process called necroptosis (Degterev et al., 2005, Teng et al., 2005b). Necroptosis 
is somewhat in between apoptosis and necrosis. In some studies, necroptosis has also 
been connected to oxidative stress and production of reactive oxygen species (ROS) (Tait 
and Green, 2008, Cauwels et al., 2003). I have summarized the comparison of apoptosis, 
necrosis and necroptosis in figure 1. and table 1. 
 
 
 
 
 
 
Figure 1. Division of cell death types. 
 
 
 
 10 
Table 1. Main similarities/differences between apoptosis, necroptosis and necrosis. 
Apoptosis Necroptosis Necrosis 
Caspase-dependent Caspase-independent Caspase-independent 
Active process Active process Passive process 
Programmed Programmed 
Pathological, activates the 
immune system  
Nuclear chromatin  Partial nuclear chromatin  
condensation and  condensation, no  Chromatin clumping 
fragmentation fragmentation   
Cleavage of caspase    
targets in mitochondria  Swelling of cristae   
Rapid loss of mito- Gradual loss of mito- Mitochondrial disruption & 
chondrial memrane chondrial memrane  dysfunction 
potential potential   
Blebbing of plasma Lacerated plasma Lacerated plasma 
membrane membrane membrane  
 
 
1.1.1 Molecular mechanisms of different types of cell death 
 
1.1.1.1 Death receptor pathways 
 
Death receptors are cell surface receptors, which can mediate cell death through binding 
with the specific ligands. This pathway is also called the “extrinsic cell death pathway” 
(Loh et al., 2006). Death receptors mainly belong to the tumour necrosis factor receptor 
(TNFR) family, and e.g. Fas and p75 neurotrophin receptors (p75NTR) are two well-
known members in this group (Zampieri and Chao, 2006). Both of these receptors can 
activate the upstream caspase, caspase-8 cascade, and may also mediate the activation of 
Nuclear Factor κB (NFκB) and c-Jun N-terminal Kinase (JNK) (Barnhart et al., 2004, 
Kreuz et al., 2004, Waterston and Bower, 2004, Sancho-Martinez and Martin-Villalba, 
2009). Especially NFκB is a pathway which is going to reappear later in this thesis. 
 
Death receptors triggered apoptosis is well-characterized. However, recently it has been 
reported that death receptors can initiate caspase-independent, necroptotic cell death as 
well. It has been shown that mice treated with TNF together with caspase inhibitor died 
very fast, causing a huge upregulation of reactive oxygen species (ROS) (Cauwels et al., 
2003). Necroptosis can also be induced by Fas (Tait and Green, 2008). Because 
necroptosis is linked to cell death caused by oxidative stress, it is worth concentrating on 
here. 
 
Receptor-interacting protein-1 (RIP-1) kinase has an important function in death 
receptor-induced necroptosis (Tait and Green, 2008, Kelliher et al., 1998, Holler et al., 
2000). It interacts both with the Fas-receptor (FasR), and the TNF-receptor (TNFR) (Hsu 
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et al., 1996). Activation of pro-survival protein NFκB also requires the intermediate 
domain of RIP-1, and that is why it cannot inhibit necroptosis of cells stimulated by 
TNFα without RIP-1 (Ting et al., 1996). One possible mechanism behind RIP-1 
mediated necroptosis is TNFα-induced, RIP-dependent inhibition of adenosine 
diphosphate (ADP) -transportation into mitochondria, which will result in reduced 
adenosine triphosphate (ATP) and cell death (Tait and Green, 2008, Temkin et al., 2006). 
This further leads to mitochondrial dysfunction, which is known to be the cause of ROS 
production (Galluzzi and Kroemer, 2008). Another mechanism by which RIP-1 can 
mediate necroptotic cell death is reduction of caspase-8. Cells normally require a small 
amount of caspase-8 to stay viable, and reduction of caspase-8 expression induces 
necroptotic cell death (Yu et al., 2004). This is RIP-1- and JNK -dependent and comes up 
through (macro)autophagy. Autophagy (or autophagocytosis) is a cellular process which 
regulates degradation of elements of cells through lysosomal machinery. It has a role in 
protection of organisms in versatile pathological conditions like infections, cancer and 
neurodegeneration (Levine and Kroemer, 2008). Recently, it has been expressed that 
TNFα can induce cell death through two separate caspase-8 activation pathways which 
are regulated by cellular Inhibitor of Apoptosis Protein 1/2 (cIAP1/2) and cellular FLICE 
(FADD-like IL-1β-converting enzyme)-inhibitory protein (c-FLIP) (Wang et al., 2008). 
The cIAP regulated pathway is RIP-1 kinase independent while c-FLIP mediated 
pathway requires RIP-1 kinase. 
 
 
1.1.1.2 Mitochondrial pathway 
 
Mitochondria are membrane-enclosed cell organelles which are required to produce 
energy in the cell by generating ATP, and are involved in processes like cell death and 
growth, cell signalling, differentiation and control of the cell cycle (McBride et al., 2006). 
Various damages can occur if there is some failure in these processes, i.e. mitochondrial 
outer membrane permeabilisation (MOMP) leads to releasing of some mitochondrial 
intermembrane space (IMS) proteins, and following this, disruption of mitochondrial 
function, and/or induction of cell death (Tait and Green, 2008). These IMS-proteins 
include cytochrome-c, apoptosis-inducing factor (AIF), Second mitochondria-derived 
activator of caspase / Direct Inhibitor of Apoptosis-Binding protein with LOw pI 
(Smac/DIABLO), and Omi / High-temperature requirement serine protease A2 
(Omi/HtrA2) (Tait and Green, 2008, Du et al., 2000, Susin et al., 1999, Verhagen et al., 
2000, Suzuki et al., 2001c). Mitochondria mediated cell death can also be called the 
“intrinsic cell death pathway”. 
 
Both cytochrome-c and AIF have important roles in mitochondrial respiration. One of the 
key events in the mitochondrial pathway is the release of cytochrome-c into the cytosol. 
Lack of cytochrome-c can lead to a burst of ROS generation because of respiratory 
dysfunction (Mootha et al., 2001, Zhao et al., 2003, Ow et al., 2008). Lack of AIF on the 
other hand leads to inhibition of mitochondrial respiratory chain complex I activity and 
compensation of oxidative phosphorylation (Vahsen et al., 2004). IAP-antagonists 
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Smac/DIABLO and Omi/HtrA2 are normally localised in the mitochondria, but in the 
presence of apoptotic stimuli they are released into the cytosol (Vaux and Silke, 2003, 
Wilkinson et al., 2004a, Wilkinson et al., 2004b, Nakka et al., 2008). Smac/DIABLO and 
Omi/HtrA2 both have pro-apoptotic effects because they can bind to IAPs and promote 
cell death (Du et al., 2000, Vaux and Silke, 2003, Nakka et al., 2008).  
 
 
1.1.2 Caspases and other pro-apoptotic proteins involved in cell death 
 
Caspases (or cysteine aspartases) are intracellular proteases which are essential for the 
apoptotic cell death process in the most cells. The importance of caspases in apoptosis 
was established when it was found that the cell death abnormal-3 (ced-3) gene was 
required for the cell death during the development of Caenorhabditis elegans (C. 
Elegans). C. Elegans is a powerful model to study cell death pathways because there is a 
remarkable degree of conservation in apoptotic pathways of nematodes and mammals 
(Ellis and Horvitz, 1986, Peden et al., 2008, Metzstein et al., 1998). In this nematode, 
131 of it’s 1091 cells die via apoptosis (Ellis and Horvitz, 1991). C. Elegans has at least 
15 genes which are involved in programmed cell death, and they can be divided into four 
groups according to their functions: 1) Decision-making (ces (cell death specification) -1 
and -2)); 2) Execution (ced-3, -4, -9, and egl (egg laying defective) -1); 3) Engulfment of 
dying cells (ced-1, -2, -5, -6, -7, -10 and -12); and 4) Degradation of cell corpses (nuc 
(nuclease) -1).  
 
It was found in 1993 that ced-3 encodes a member of caspase-family with similar 
properties to the mammalian interleukin-1-beta converting enzyme (ICE) (now known as 
caspase-1), which was the first known caspase (Yuan et al., 1993). Caspases can be 
divided into groups in different ways. One common way is to divide them into initiator 
(apical) caspases, and effector (executioner) caspases (Salvesen and Riedl, 2008). 
Initiator caspases (-2, -8, -9, and -10) are activated in response to apoptotic stimuli, and 
they cleave inactive pro-forms of effector caspases. This leads to activation of effector 
caspases (i.e. -3, -6, and -7), and they in turn cleave other protein substrates within the 
cell, triggering the apoptotic process. Another way is to divide caspases according to their 
substrate specificity (Thornberry et al., 1997). Group I caspases (-1, -4, -5, and -13) have 
hydrophobic amino acids in the position P4 of the cleavage site. In group II caspases (-2, 
-3, and -7) the aspartic acid (Asp; amino acid) is essential in the same position, and in 
group III caspases (-6, -8, and -9) there has to be an aliphatic amino acid in position P4. 
In addition to apoptosis during adult life and development, some caspases are also 
involved in the immune system. For example, caspase-8 is required for appropriate 
function of cell death cascades where cytokines like TNF and Fas/Apo1 are involved 
(Varfolomeev et al., 1998). Failure to undergo apoptosis is one of the main contributions 
to tumour development and autoimmune diseases, while the unwanted apoptosis occurs 
in ischemia and neurodegenerative diseases.  
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1.2 Anti- and pro-apoptotic proteins  
 
Defects in regulation of cell death can occur in many diseases. Excessive cell loss is 
common to diseases like neurodegeneration, stroke, and heart failure; and cell 
accumulation occurs in diseases like cancer, autoimmunity, and inflammation (Jana and 
Paliwal, 2007).  
 
1.2.1 B-cell lymphoma 2 (Bcl-2) family proteins 
The Bcl-2 proto-oncogene was first discovered in 1985 from human follicular B cell 
lymphoma (Bakhshi et al., 1985, Cleary and Sklar, 1985, Tsujimoto et al., 1985). The 
family of Bcl-2 proteins forms a critical intracellular checkpoint in the intrinsic pathway 
of apoptosis (Danial and Korsmeyer, 2004). They control MOMP, and they can be either 
pro- or anti-apoptotic. The Bcl-2 family proteins can be structurally divided into three 
subfamilies: the Bcl-2, Bcl-2-associated X protein (Bax) and Bcl-2 homology (BH) 3-
only. I will not go into Bcl-2 in greater detail, because I haven’t concentrated on it in my 
studies. 
 
1.2.2 Inhibitor of Apoptosis Protein (IAP) family  
The Inhibitor of Apoptosis Protein (IAP) gene was identified in baculovirus infected 
Spodoptera frugiperda SF-21 insect cells in 1993 (Crook et al., 1993). IAP family 
members can inhibit apoptosis through different mechanisms of which inhibition of 
caspases is the most well-known. IAP family members can be divided into several groups 
based on the presence of baculovirus IAP repeats (BIR) domains at the amino terminus of 
the protein (Wei Y et al., 2008) (figure 2). There are three subtypes of BIR domains: 
BIR1, -2 and -3. At the carboxyl terminus some of the IAPs have Really Interesting New 
Gene (RING) zink-finger domain. Ubiquitin-conjugating (UBC) domain can also be 
found in proteins belonging to the IAP Family (Lewis and Holcik, 2005, Eckelman et al., 
2006).  
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Figure 2. IAP family members can be divided according to their structures. XIAP, and 
Neuronal Apoptosis Inhibitor Protein (NAIP) all have three BIR domains and a RING 
domain. Survivin has only one BIR domain, and Livin one BIR domain and a RING 
domain. BRUCE, a giant protein member of this family, has one BIR domain and an 
UBC domain.  
 
 
1.2.2.1 X-linked Inhibitor of Apoptosis Protein (XIAP)  
 
XIAP (also called as baculoviral IAP repeat-containing 4 (BIRC4), or human IAP-like 
Protein (hILP); 57 kDa) is the most-well characterized protein among IAPs. It is 
expressed both during development and in the adult brain (Korhonen et al., 2001). As the 
name suggests, XIAP gene is located in the X chromosome. It has been shown in different 
cell types that overexpression of XIAP protects against various injuries and cell 
degeneration (Holcik et al., 2001, Perrelet et al., 2002, Trapp et al., 2003). XIAP prevents 
cell death through various signalling cascades (figure 3), and it has the ability to 
effectively prevent cell death caused by TNF-α, Fas, UV light, and genotoxic agents 
(Duckett et al., 1998).  
 
XIAP contains three N-terminal BIR domains and a C-terminal RING domain (figure 4). 
BIR1 can interact with TGF-beta (β) activated kinase 1 (TAK1) binding protein 1 
(TAB1) which is crucial for XIAP-induced activation of NFκB and TAK1 (Lu et al., 
2007). TAK1 is a mitogen-activated protein (MAP) kinase kinase kinase (MKK3), and it 
activates NFκB and JNK-p38 kinase pathways by directly phosphorylating the inhibitor 
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of kappa B kinase (IKK) and MKK6 (Wang et al., 1998). NFκB is a transcription factor 
which has several functions in the body, e.g. it regulates genes which control cell survival 
and proliferation, and it plays a key role in regulating the immune response to infection. 
Both NFκB and JNK-p38 mitogen-activated kinases are responding to stress stimuli such 
as cytokines or ultraviolet irradiation. The JNK-p38 system is also involved in T cell 
differentiation and apoptosis.  
 
BIR2 and BIR3 domains of XIAP are essential for the prevention of cell death caused by 
particular caspases. BIR2 domain of XIAP, together with the linker region between BIR1 
and BIR2, are responsible for inhibition of caspase-3 and -7 (Chai et al., 2001, Huang et 
al., 2001, Riedl et al., 2001, Suzuki et al., 2001b). Via BIR3 XIAP prevents activation of 
caspase-9 and a mitochondrial protein called Smac/DIABLO (Chai et al., 2000, Liu et al., 
2000, Srinivasula et al., 2001, Shiozaki et al., 2003). Binding of Smac/DIABLO to IAPs 
promotes e.g. activation of pro- and mature caspase-3 (Chai et al., 2000).  
 
The main function of RING finger domain is to mediate autoubiquitinylation and 
ubiquitinylation of other proteins (Freemont, 2000, Richter and Duckett, 2000, Yang et 
al., 2000, Vaux and Silke, 2005). Ubiquitinylated proteins are labelled for proteasomal 
degradation. Ubiquitinylation controls the stability, function and intracellular localisation 
of several proteins. Ubiquitin ligase activity of XIAP enhances its cell death preventing 
effects in Fas-induced cell death, and deletion in the RING domain sensitizes MEFs to 
TNFα (Suzuki et al., 2001a, Schile et al., 2008). This indicates that ability of XIAP to 
inhibit the activation of death receptor signalling depends at least partly on the presence 
of the RING domain. 
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Figure 3. XIAP prevents cell death through various signalling cascades. The most well 
known mechanism is the ability of XIAP to inhibit caspases. Through caspase-9 and 
Apoptotic Protease Activating Factor (APAF), XIAP can modulate the mitochondrial cell 
death pathway, while Smac/DIABLO and HtrA2/Omi have opposite effects on cell death 
compared with XIAP. Via JNK and NFκB XIAP is able to modulate cell death and the 
transcription of other genes involved in cell death. Through TAK1 XIAP is also 
connected to death receptor signalling.  
 
 
 
Figure 4. The structure of XIAP has three BIR domains and a RING domain. XIAP is 
able to prevent various types of cell death and each domain of XIAP can affect cell death 
processes in different ways. Some of the linker regions between domains are required for 
the actions of XIAP as well. 
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1.3 Oxidative stress and intracellular antioxidant enzymes 
 
Molecular oxygen is used for many cellular reactions such as catalysis and energy 
production. These reactions in turn produce ROS, which are normal by-products of 
cellular metabolism and normally eliminated by intracellular antioxidant enzymes. 
Oxidative stress is the result of an imbalance in the cellular pro-oxidant/antioxidant 
homeostasis which leads to the overproduction of ROS, and it can follow e.g. from 
environmental factors, neurodegeneration or inflammation (Barnham et al., 2004). 
Oxidative stress can cause mitochondrial dysfunction such as reduced ATP production, 
decreased ubiquitin proteasome system (UPS) function, and impaired calcium 
homeostasis. Structural and functional disintegration of cells, induced by overproduction 
of ROS, can be mediated through various mechanisms like lipid peroxidation, 
sulfhydroxyl oxidation, proteolysis, and shearing of the nuclear material (Loh et al., 
2006). These in turn cause cell death by apoptosis, necroptosis or necrosis. In the past, 
direct treatment with oxidants was thought to induce solely necrosis. However, later 
studies showed that lower doses of free radicals can trigger apoptosis as well, and more 
recent studies have considered the purpose of necroptosis in cell death caused by 
oxidative stress (Tait and Green, 2008, Cauwels et al., 2003, Loh et al., 2006). The 
contribution of ROS in different cell death types is highly cell-type specific, and also 
depends on the amount of endo- or exogenously generated ROS present (Nakano et al., 
2006). ROS can induce apoptosis through a mitochondria-dependent pathway mediated 
by activation of JNK, or it can act directly on the mitochondria resulting in the release of 
apoptotic factors such as cytochrome-c, AIF, or Smac/DIABLO. Necrosis (and 
necroptosis) caused by ROS can be mediated through death receptor induced pathways, 
and it is typical during overproduction of ROS that JNK is chronically activated (Nakano 
et al., 2006, Sakon et al., 2003, Nakano, 2004, Nakano, 2005). 
 
The brain is very sensitive to oxidative damage because of its high oxygen consumption. 
It is known that oxidative stress is involved e.g. in neurodegenerative diseases such as 
Huntington’s, Parkinson’s, and Alzheimer’s diseases, and in inflammatory diseases like 
inflammatory joint disease (Barnham et al., 2004, Henrotin et al., 2003, Rego and 
Oliveira, 2003, Afonso et al., 2007). It is not fully clear, whether the overproduction of 
ROS is a cause or a consequence in these diseases. Anyhow, ROS can damage the 
respiratory components which further increase the production of free radicals, and that 
way potentiate the whole damaging effect. 
 
 
1.3.1 Elimination of ROS with intracellular antioxidant scavenger enzymes 
 
ROS are small molecules or atoms which have unpaired valence shell electrons, and they 
rapidly accept another electron or transfer the unpaired electron to another molecule. 
ROS are mainly developed in mitochondria (Reddy, 2006). Under normal conditions, 
there is a balance between pro- and antioxidant proteins within the cells, where increased 
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levels of ROS are counteracted by antioxidant systems including superoxide dismutases 
(SODs), and thioredoxins (TRXs).  
 
SODs are intracellular antioxidants which catalyse the reaction of a highly reactive 
oxygen radical called the superoxide anion (O2-) to alter dioxygen (O2) and hydrogen 
peroxide (H2O2):  
2O2- + 2H+ → H2O2 + O2 
SODs are named or numbered according to their location within cell organelles: 
1. SOD1 can be found in the cytoplasm, nucleus and intermembrane space of 
mitochondria. It contains copper (Cu) and zinc (Zn), which is why it is also called 
Cu/Zn-SOD. Expression of SOD1 can be inhibited e.g. by tumour necrosis factor –α 
(TNFα) and this explains why there is O2- and derivatives in inflammatory conditions 
(Afonso et al., 2006). TNFα inhibits SOD1 through the JNK/AP-1 pro-apoptotic 
pathway.  
2. SOD2 is located in mitochondria. It uses manganase (Mn) as a cofactor, and it can be 
also called Mn-SOD. SOD2 can be activated e.g. by pro-inflammatory cytokines such 
as interleukin-1, -4, and -6 (IL-1, IL-4 and IL-6), and TNFα. The promoter region 
involved in activation of SOD2 contains sites that bind to transcription factors 
belonging to the families of nuclear factor κB (NFκB), CCAAT/enhancer-binding 
protein (C/EBP) and nuclear factor-1 (NF-1) (Kiningham et al., 2001).  
3. SOD3 is an extracellular protein (EC-SOD), and it also uses Cu and Zn as cofactors - 
same way as SOD1. I will not go into this in more detail, because in our studies we 
have investigated mainly the intracellular SOD enzymes. 
 
Hydrogen peroxide, which has been generated after reactions mentioned above, is also a 
pro-oxidant, although not as reactive as O2-. H2O2 can further be eliminated by an 
intracellular antioxidant enzyme catalase to water (H2O) and molecular oxygen (O2):  
2H2O2 → O2 + 2H2O (catalase) 
Catalase is a heme-containing enzyme localised mainly in the peroxisomes (Nordberg 
and Arner, 2001, Maulik and Das, 2008). H2O2 can also be eliminated by the intracellular 
antioxidant enzyme glutathione peroxidase (GPx). There are several isozymes of GPx, 
which have various cellular locations and substrate specificities. GPx1 is the most 
abundant version, and it is localised in the cytoplasm. The way it converts H2O2 to water 
differs from the way catalase catalyses that reaction: 
2GSH + H2O2 → GSSG + 2H2O (GPx) 
In this reaction GSH represents a monomeric glutathione and GSSG glutathione 
disulfide. After this reaction an enzyme called glutathione reductase (GSR) completes the 
cycle by reducing the oxidized glutathione:  
GSSG + NADPH + H+ → 2 GSH + NADP+ (GSR) 
 
A less well studied enzymatic intracellular antioxidant system is the thioredoxin system, 
which consists of thioredoxin (TRX), thioredoxin reductase (TRXR), and NAPDH 
(Maulik and Das, 2008). These TRX family proteins take part in redox reactions and in 
cellular defense against ROS (Takagi et al., 1999, Patenaude et al., 2004). There are two 
main isoforms of TRX protein: TRX1 is a “classical”, cytosolic, and the most studied 
form of TRXs; and TRX2 is a less studied protein with mitochondrial translocation 
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(Nordberg and Arner, 2001, Maulik and Das, 2008, Spyrou et al., 1997, Taniguchi et al., 
1996). TRX system is highly effective in reducing disulfides of other proteins and 
peptides: 
TRX-(SH)2 + Protein-S2/Substrateoxized → TRX-S2 + Protein-(SH)2/Productreduced 
The oxidised TRXs are reduced and kept in a reduced state by TRXR, which completes 
the cycle by reducing the active site disulfide of TRX: 
TRX-S2 + NADPH + H+ → TRX-(SH)2 + NADP+ 
 
Altogether, by influencing intracellular antioxidant proteins, it could be possible to 
improve the state of oxidative stress as well.  
 
 
1.4 Transcription factor Nuclear Factor kappa B (NFκB) 
 
NFκB is a nuclear transcription factor that was first identified in 1986 (Sen and 
Baltimore, 1986). It was named according to its localisation when it was first found: in 
the nucleus, bound to an enhancer element of immunoglobulin κ light chain gene in B 
cells. NFκB is expressed almost in all animal cell types, and it is involved in several 
cellular responses to various stimuli, such as stress, cytokines and free radicals. 
Conversely, incorrect regulation of NFκB has been linked to various diseases, i.e. cancer, 
inflammatory diseases, and neurodegenerative diseases. 
 
 
1.4.1 Structure of NFκB 
 
All proteins of the NFκB/Rel family share a Rel homology domain (RHD) in their N-
terminus. There are five proteins in NFκB/Rel family: NFκB1 (p50 and its precursor 
p105), NFκB2 (p50 and its precursor p100), RelA (p65), RelB, and c-rel (Siebenlist et al., 
1994, Karin and Ben-Neriah, 2000). Those can be further divided into two protein 
subfamilies (table 2). NFκB1 and NFκB2 proteins are synthesized as large precursors 
(p105 and p100), and they undergo the ubiquitin/proteasome system mediated process to 
generate the mature NFκB subunits (p50 and p52). This process involves selective 
degradation of their C-terminal region containing ankyrin repeats, while RelA, RelB, and 
c-Rel have a transactivation domain in their C-terminus. 
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Table 2. Classification of NFκB family proteins 
Subfamily 
I 
NFκB1/p105 → 
p50 
  
NFκB2/p100 → 
p52 
  RelA/p65 
Subfamily 
II RelB 
  c-rel 
 
 
1.4.2 Activation of NFκB 
 
All of the NFκB/Rel family proteins have a 300-amino acid Rel homology region, which 
is responsible for their main actions. They can form both homo- and heterodimers, and 
the most commonly known NFκB complex consists of p50/p65 heterodimer, which is 
also the most often used term to describe NFκB. The inactive state of NFκB is bound by 
inhibitory complex IκB, which holds it as a cytoplasmic protein complex. Upon 
stimulation, the IκB subunit is phosphorylated by IκB kinases (IKKα and IKKβ), and in 
the classic NFκB model IκBα is transiently degraded by UPS, with consequent release of 
dimers of p65/p50 to translocate into the nucleus (Hacker and Karin, 2006, Sethi et al., 
2008) (figure 5). In the nucleus they bind to DNA target sites (known as “κB sites”), and 
directly regulate gene expression of numerous genes. This whole reaction is usually rapid 
(within the first hour after stimulation).  
 
 
Figure 5. The most classic model of how the NFκB pathway can be activated. 
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Later it has been shown that NFκB activation is actually a biphasic reaction (Ladner et 
al., 2003, Caba and Bahr, 2004, Miskolci et al., 2007). The later phase can exist about ten 
hours after continuous stimulation, and activation can still exist even the following day. It 
is also possible that NFκB is persistently activated if stimulation is continuous (Miskolci 
et al., 2007). A common feature in to this “late-phase activation of NFκB” is that the 
activation can be IκBα-independent, or IκBα is only partly degraded (Ladner et al., 2003, 
Miskolci et al., 2007). Degradation of IκBβ can also be involved in the later phase 
(Ladner et al., 2003, Caba and Bahr, 2004). It is also probable that distinct phases of 
NFκB activation regulates different genes, of they even may lead to opposing cellular 
responses (Caba and Bahr, 2004). 
 
 
1.5 Neurotrophic factors 
 
Neurotrophic factors are growth factor proteins which have a numerous amount of 
functions in the central nervous system (CNS) and peripheral nervous system (PNS) in 
developing and adult mammals (Allen and Dawbarn, 2006). They are involved in 
different cell signalling processes like cell survival, differentiation and growth. The group 
of neurotophic factors includes: 1) neurotrophins (NTs) such as nerve growth factor 
(NGF), brain-derived neurotrophic factor (BDNF), and neurotrophins 3 and 4 (NT-3 and 
NT-4); 2) neurokines like ciliary neurotrophic factor (CNTF); and 3) glial cell line-
derived neurotophic factor (GDNF) family ligands (GFLs) (Airaksinen and Saarma, 
2002, Bespalov and Saarma, 2007). Recently a new neurotrophic factor called conserved 
dopamine neurotrophic factor (CDNF) was discovered in Helsinki (Lindholm et al., 
2007). It differs from neurotrophins and GDNF structurally and functionally. CDNF has 
a neurotrophic activity specifically for brain neurons and particularly for dopaminergic 
neurons in vivo. Loss of neurotrophic factors and their activity have been connected to 
different neurodegenerative diseases. NGF and tropomyosin-related kinase (Trk) A 
receptor may play a role in Alzheimer's disease (AD), and BDNF in Huntington’s 
Disease (HD). In vivo results suggest that both GDNF and CDNF could be powerful tools 
in the treatment of Parkinson's disease (PD) (Lindholm et al., 2007, Dawbarn and Allen, 
2003).  
 
 
1.5.1 Neurotrophins 
 
Neurotrophins are all synthesized as precursors (“pre-pro-form”), and whereas pro-NGF, 
pro-NT-3, and pro-NT-4 are packaged into constitutive vesicles before secretion, pro-
BDNF is mainly packaged into regulated secretory pathway vesicles, and secreted in an 
activity-dependent manner (Allen and Dawbarn, 2006, Mowla et al., 2001, Hibbert et al., 
2003). The pre-region of the protein is cleaved during secretion in the endoplasmic 
reticulum (ER), and after that, the pro-from is cleaved in the Golgi or in the secretory 
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granules (Seidah et al., 1996, Thomas and Davies, 2005). At least pro-forms of BDNF 
and NGF are secreted without being cleaved and while mature forms of neurotrophins 
have usually neuroprotective properties, these pro-forms have mainly pro-apoptotic 
functions (Nykjaer et al., 2005). 
 
Neurotrophins can act through two different receptor types: 1) the family of tyrosine 
kinase Trk receptors; and 2) the “pan” neurotrophin receptor called p75NTR (p75 
neurotrophin receptor). Trk receptors are activated by binding of specific ligands to their 
extracellular domains. Activated receptors act like tyrosine kinases. This means that they 
are able to phosphorylate certain tyrosines, and so activate signalling processes within the 
cell. Trk receptors have various subtypes (A-C), and each of them binds to a spesific 
group of neurotrophins:  TrkA binds NGF, TrkB binds both NT-4 and BDNF, and TrkC 
binds NT-3. p75NTR belongs to the TNFR-family, and all neurotrophins bind to it with 
similar affinity. Upon binding of pro-neurotrophins, p75NTR can activate apoptosis 
through its intracellular “death domain” (Nykjaer et al., 2004, Teng et al., 2005a). 
 
Many investigations indicate that the survival-promoting signals of neurotrophins are 
generated by activation of Trk receptors, and that their death-promoting signals are 
generated by activation of p75NTR receptors (Kalb, 2005). There is also an assessment 
that mature forms of neurotrophins bind to Trk receptors promoting cell survival, and 
pro-forms to p75NTR receptors promoting cell death. Preferentially it goes this way, but 
there is evidence that pro- and mature forms of neurotrophins can also bind to both 
receptor types and activate survival-promoting and death-promoting pathways. Thus, 
NGF promotes the survival of sensory neurons by activation of NFκB, and this seems to 
be mediated by p75NTR, and on the other hand, pro-neurotophins bind weakly to Trk 
receptors as well (Hamanoue et al., 1999, Lee et al., 2001). There are also indications for 
crosstalk between Trk and p75NTR receptor pathways: activation of p75NTR receptor may 
lead to enhance the affinity of neurotrophins to bind to the Trk receptors, and thereby 
promote positive signalling of neurotrophins (Zampieri and Chao, 2006, Kalb, 2005).  
 
 
1.5.1.1 Brain-derived neurotrophic factor (BDNF) 
 
BDNF is a well-known neurotrophic factor which promotes neuronal survival, growth 
and differentiation of new synapses and neurons, and induces neuronal plasticity 
(Acheson et al., 1995, Huang and Reichardt, 2001, Greer and Greenberg, 2008, 
Matsumoto et al., 2008). It is expressed in specific brain areas, such as hippocampus, 
cortex, and basal forebrain, which are essential to learning, memory, and cognition 
(Yamada and Nabeshima, 2003). BDNF also plays an important role in neural 
development and it is one of the most active neurotrophins in helping to control and 
stimulate neurogenesis (Ernfors et al., 1995, Zigova et al., 1998, Benraiss et al., 2001, 
Pencea et al., 2001). 
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The BDNF protein is coded by the BDNF gene which is located on chromosome 11 in 
humans (Jones and Reichardt, 1990, Maisonpierre et al., 1991). The BDNF protein is 
synthesized as a 36 kDa precursor protein which is post-translationally converted into 14 
kDa, mature BDNF. Recent studies using mouse hippocampal neurons indicate that small 
amounts of pro-BDNF is also released from neurons (Matsumoto et al., 2008). Mature 
BDNF binds both to the TrkB and p75NTR receptors. and pro-BDNF can also bind to both 
receptors. It has been shown that pro-BDNF can induce apoptosis through the p75NTR and 
sortilin receptor complex (Teng et al., 2005a). In pathological conditions of the brain one 
possible reason for neuronal loss can be an overproduction of pro-neurotrophins (Volosin 
et al., 2006). Usually donwregulation of mature BDNF is also involved. BDNF has been 
linked to various diseaseses such as Huntington’s Disease, Parkinson’s Disease, 
Alzheimer’s Disease and depression (Zuccato et al., 2003, Brunoni et al., 2008, Dwivedi, 
2009, Zajac et al., 2009, Zuccato and Cattaneo, 2009).  
 
 
1.6 Huntington’s Disease (HD) and oxidative stress  
 
1.6.1 Background of HD 
 
HD has been named after George Huntington’s description of this particular condition 
which is also known as chorea (the Greek word for dance) (Huntington G., 1872). 
Prevalence of HD in the whole world is about 5-10/100 000 (Landles and Bates, 2004). 
Patients are about 30-50 years old at the onset of disease and they usually die in 10-20 
years after the first symptoms. Physical symptoms of HD are i.e. bradykinesia, 
clumsiness and defects in voluntary movements (Thompson et al., 1988, Gil and Rego, 
2008). These are usually accompanied with cognitive and psychiatric symptoms like 
impaired executive functions or depression (Walker, 2007). Neuropathological changes 
of HD occur in various brain regions but the primary site of neurodegeneration is in the 
striatum (caudate and putamen) and specially the striatal medium spiny neurons are the 
most susceptible (Walker, 2007, Vonsattel and DiFiglia, 1998, Browne and Beal, 2006) 
The largest part of the cell death happens in striatum but it has been shown that cell death 
occurs also in cerebral cortex, hippocampus and thalamus (Vonsattel et al., 1985, 
Cudkowicz and Kowall, 1990, Hedreen et al., 1991, Spargo et al., 1993). Striatal atrophy 
begins a long time before HD is diagnosed. 
 
HD is caused by the expansion of the repeat in a gene called huntingtin (HTT). HTT, also 
referred to as interesting transcript 15 (IT15), was discovered in 1993 and mutation in 
this gene is involved in pathogenesis of HD (A novel gene containing a trinucleotide 
repeat that is expanded and unstable on huntington's disease chromosomes. the 
huntington's disease collaborative research group. 1993). Exon 1 of the coding region of 
the HTT gene contains a DNA-segment known as a CAG trinucleotide (glutamine) 
repeat. Expansion of this repeat site in HTT gene and it is leading to the formation of 
intracellular and intranuclear aggregates of misfolded huntingtin protein (Zoghbi and Orr, 
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2000, Li and Li, 2004). Normal individuals have < 35 CAG repeats. However, alleles 
with 35-39 CAG repeats are connected with late onset HD, while 40-50 repeats are 
common in adult-onset and the longest (> 70) repeats are involved in the most severe, 
juvenile and infantile HD-cases (A novel gene containing a trinucleotide repeat that is 
expanded and unstable on huntington's disease chromosomes. the huntington's disease 
collaborative research group. 1993). In other words, the number of CAG repeats is 
associated with the age of onset of HD, which is also typical in other polyglutamine 
diseases.  IT15 encodes a huge protein called huntingtin (htt), with molecular weight of 
348 kDa. Wild-type huntingtin has an important role in normal embryonic development 
and neuronal survival (Reiner et al., 2003). It’s localised in cytoplasm and organelles 
such as mitochondria, Golgi apparatus, endoplasmic reticulum, synaptic vesicles, and 
several components of the cytoskeleton but small amounts of it also occurs inside the 
nucleus (Gil and Rego, 2008, Hoogeveen et al., 1993, Kegel et al., 2002). Huntingtin has 
been implicated i.e. in transcriptional regulation, endocytosis and intracellular 
transportation.  
 
 
1.6.2 The roles of oxidative stress and BDNF in HD 
 
ROS, mitochondrial dysfunction and metabolic impairment are known to be involved in 
several neurodegenerative diseases (Trushina and McMurray, 2007, Imarisio et al., 
2008). It still not clear, whether these are causes or consequences of the disease but 
results from both post-mortem brains of HD patients and transgenic mouse models of HD 
suggest that they could have an important role in HD pathogenesis (Imarisio et al., 2008, 
Mangiarini et al., 1996, Tabrizi et al., 1999). The length of CAG repeats of HTT is 
closely linked to mitochondrial function. Mitochondrial impairment and oxidative stress 
have even been discovered in asymptomatic carriers of HD (Saft et al., 2005). Studies in 
post-mortem tissue of HD patients have shown several other pathological changes in HD 
brain which can be connected to oxidative stress and metabolic and mitochondrial 
dysfunction (Gil and Rego, 2008). It has been shown that both mitochondrial ATP/ADP 
production and calcium handling decreases if the number of CAG repeats increases 
(Seong et al., 2005, Oliveira et al., 2006). This happens because impaired energy 
metabolism caused by enhanced CAG repeats leads to reduced mitochondrial membrane 
potential when mitochondria cannot handle calcium normally, and they will be more 
sensitive to calcium influx and excitotoxicity (Oliveira et al., 2006, Novelli et al., 1988, 
Fagni et al., 1994). In normal situations, oxidative stress should be in balance with 
antioxidant proteins of the body.  
 
Huntigtin together with Huntingtin-Interacting Protein 1 (HIP1) and Huntintin-
Associated Protein 1 (HAP1) have roles in endocytosis and vesicle transportation (Velier 
et al., 1998). Mutant huntingtin causes e.g. impaired transportation of vesicles, and one 
important change after this is attenuated BDNF transportation, which leads to deprivation 
of neurotrophic support (Gil and Rego, 2008, Gauthier et al., 2004). Loss of BDNF gene 
transcription mediated by mutant huntingtin has been demonstrated in an HD-model, 
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while wild-type huntingtin was shown to upregulate the transcription of BDNF (Zuccato 
et al., 2001, Cattaneo et al., 2005). Expression of BDNF is regulated by the protein 
repressor element-1 silencing transcription factor/neuron restrictive silencer factor 
(REST/NRSF) (Zuccato et al., 2003). In the normal situation, wild-type huntingtin binds 
to REST/NRSF, and the reduction of REST/NRSF activity leads to enhanced expression 
of BDNF but mutant huntingtin has a failure to bind to REST/NRSF, which is why 
transcription of BDNF is repressed. BDNF has a crucial role in cell survival of striatal 
neurons and in the activity of cortico-striatal synapses.  
 
There is also a long list of other transcription factors which are known to interact with 
huntingtin. Cyclic AMP-response element binding (CREB) protein (CBP), nuclear factor 
–κB (NFκB) and p53 are few examples of transcription factors which are affected by 
CAG expansion (Steffan et al., 2000, Roze et al., 2008). Within past few years it has been 
noticed that mutant huntingtin can also prevent the expression of Peroxisome 
proliferator-activated receptor Gamma (γ) Co-activator 1 alpha (PGC1α) (Cui et al., 
2006, Weydt et al., 2006). This leads to reduced expression of PGC1α mitochondrial  
target genes such as antioxidant enzymes superoxidase dismutase 2 (SOD2) (St-Pierre et 
al., 2006). All the transcription factors or co-factors mentioned above are known to be 
somehow in connection with oxidative stress, cell survival and/or BDNF, which makes 
these pathways really interesting subjects to study. 
 
 
1.7 Resveratrol is a potent candidate in the treatment of diseases where oxidative 
stress is involved 
 
Resveratrol (3,4',5-trihydroxystilbene, RSV) is a polyphenol compound primarily found 
in grapes and red wine. RSV has a large range of biological actions including protection 
of cells against oxidative stress (Baur and Sinclair, 2006). The ability of polyphenolic 
compounds, including resveratrol, to act as antioxidants are related to redox properties of 
the phenylic hydroxyl groups and the potential for electron delocalisation across the 
chemical structure (de la Lastra and Villegas, 2007) (chemical structure of RSV in figure 
6).  
 
Already some ten years ago it was observed that RSV protected rat hearts from ischemic 
injury (Das et al., 1999, Ray et al., 1999). Later the capability of RSV to protect against 
ischemic brain damage was reported, and RSV could be useful in the treatment of 
chronic, neurodegenerative diseases like Huntington’s, Parkinson’s and Alzheimer’s 
Disease as well (Parker et al., 2005, Anekonda, 2006, Wang et al., 2006, Okawara et al., 
2007, Blanchet et al., 2008, Chao et al., 2008, Della-Morte et al., 2009).  
 
The mechanisms behind the antioxidant properties of RSV are not clear. There are data 
showing that RSV increases the activities of adenosine mono phosphate (AMP)-activated 
kinase (AMPK), silent information regulator 1 (SIRT-1), and PGC-1α (Baur et al., 2006, 
Lagouge et al., 2006). These are all connected to energy metabolism of the cells. PGC1α 
has been shown to be induced together with several intracellular antioxidant enzymes (St-
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Pierre et al., 2006). RSV is also able to affect survival pathways like NFκB and mitogen 
activated protein kinases (MAPKs) (Aggarwal et al., 2004, Kundu et al., 2004, Holme 
and Pervaiz, 2007). However, it is important to remember that the survival promoting 
effects of RSV depend on the concentration, as high concentrations of RSV can trigger 
apoptosis instead of survival (Jang et al., 1997, In et al., 2006). RSV could be a 
potentially interesting drug candidate to consider in various diseases, but the therapeutic 
window and mechanism of its action require to be determined. 
 
 
Figure 6. Chemical structure of RSV. 
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2. AIMS OF THE STUDY 
 
The purpose of this thesis is to give novel insights into the ability of XIAP to reduce 
oxidative stress, and protect cells against cell death. We have also studied oxidative stress 
in the Huntington’s disease model, and investigated the capability of resveratrol to reduce 
oxidative stress and cell death in neurons.  
 
 
The specific aims of this thesis were: 
 
• To investigate the possible role of XIAP in oxidative stress in neuronal cells  
(I, II) 
 
• To study the effects of XIAP on NFκB and BDNF signalling (I, II) 
 
• To identify the role of NFκB and oxidative stress in Huntington’s Disease (III) 
 
• To investigate if RSV is able to modulate oxidative stress in neurons, and clarify 
the mechanisms involved (IV) 
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3. MATERIALS AND METHODS 
 
The experimental methods used in this thesis are listed in table 3, and short descriptions 
of them are given below the table. More detailed descriptions are found in the original 
publications.  
 
Table 3.  Methods used in this thesis. 
Method        Publication 
Cell culture, transfections and stimulations     I, II, III, IV 
ROS measurement with FACSAria     I, III, IV 
MTT assay        I, IV 
Western Blotting       I, II, III, IV 
Immunocytochemistry      I 
Luciferase Assay       I, II, III. IV 
PCR and light cycler        I, II, III, IV 
 
 
3.1 Cell culture, transfections and stimulations 
 
PC6.3-cells were cultured in RPMI 1640 medium supplemented with 10% Horse Serum 
(HS) and 5% Fetal Calf Serum (FCS). Swiss 3T3 and immortalized fibroblast cell lines 
from NFκB RelA/p65 knockout mice were cultured in Dulbecco’s modified Eagle 
medium (DMEM) supplemented with 10% FCS. For overexpressing XIAP, both cell 
lines were transfected using expression plasmids encoding XIAP fused to Enhanced 
Green Fluorescent Protein (EGFP) (or in some experiments fused to myc) and 
TransFectin Lipid Reagent according to manufacturer’s instructions (Bio-Rad). When 
XIAP-EGFP expression plasmid was used, control cells were transfected with EGFP 
expression vectors. To induce oxidative stress, PC6.3-cells were stimulated with xanthine 
sodium and xanthine oxidase (Valencia and Moran, 2004). Aspirin (acetylsalicylic acid 
(ASA)) was used in the first (I) publication because of it’s ability to inhibit NFκB (D 
Acquisto F. et al., 2002). In some experiments of the supplementary data BAF (Boc-D-
FMK) was used to inhibit caspases. In the third (III) article PC6.3-cells were transfected 
with expression plasmids encoding different polyQ repeats (18-120 Q) of huntingtin 
exon-1 fused to EGFP for modeling HD. In the fourth (IV) study we investigated the 
effect of resveratrol on oxidative stress in PC6.3-cells. 
 
 
Hippocampal neurons were prepared from embryonic day 17 Wistar rats. E17 HC 
neurons were cultured in Neurobasal medium containing 2% B27, and transfected either 
with XIAP-myc expression plasmid or silencing RNA (siRNA) against XIAP using 
AMAXA Rat Neuron Nucleofector system. The efficiency of transfections was ensured 
by Western Blotting analysis by using specific antibody against XIAP. In certain 
experiments of the second (II) publication, neurons were stimulated with BDNF or IL-6. 
Embelin (2,5-dihydroxy-3-undecyl-1,4-benzoquinone) was used in some experiments to 
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antagonize XIAP (Nikolovska-Coleska Z et al., 2004), and recombinant TrkB⁄Fc 
chimeras to scavenge and inhibit BDNF action. Some of the cells also received an 
antibody against IL-6.  
 
 
3.2 Measurement of ROS with FACSAria 
 
Dihydroethidium (DHE) was added into the medium of PC6.3-cells for the last 15 
minutes to indicate production. After this, cells were suspended into PBS and 
immediately examined by FACSAria (BD Biosciences). First EGFP-positive cells were 
found with excitation at 488 nm and emission at 502 nm. After gating of EGFP-positive 
cell population, DHE-positivity was measured with excitation at 488 nm and emission at 
595 nm. 
 
 
3.3 Determination of cell viability with MTT assay 
 
Briefly, MTT-solution (Thiazolyl Blue Tetrazolium Bromide) was added to the cells in 
96-well plates for last 2 hours. Next, the medium was removed and isopropanol-/HCl-
solution was added. The dye formed was measured at 560 nm, and the absorbance was 
linear to the number of viable cells.  
 
 
3.4 Western Blotting Analysis 
 
In all Western Blotting experiments excluding the analysis of PARP, cells were lysed in 
RIPA buffer containing 50 mM Tris-HCl (pH 7,4), 1% NP-40, 0,25% 
natriumdeoxycholate, 150 mM NaCl, 1mM EDTA and protease inhibitors (Roche). For 
analysing PARP, cells were lysed in a buffer containing 62,5 mM Tris (pH 6,8), 6 M 
urea, 10 % glycerol, 2 % SDS, 5 % β-mercaptoethanol and 0,003 % bromophenol blue. 
In certain cases, phosphatase inhibitors were added as well. Protein concentrations were 
determined by BC Assay: protein quantitation kit. Proteins were separated using SDS-
PAGE gels by electrophoresis and transferred to a nitrocellulose membrane, blocked 
either in Tris-buffered saline (TBS) and 5% skim milk or BSA, and incubated with 
primary antibodies diluted blocking buffer. Used antibodies were against BDNF, 
catalase, p-CREB, p-IκB-α, IL-6, NFκB (p65), PARP, SOD1, SOD2, spectrin, TrkB, p-
TrkA/B, TRX2, XIAP or actin. Next day the membrane was incubated with a horseradish 
peroxidase conjugated secondary antibody, and detection was performed using the 
SuperSignalWest Pico Chemiluminescent Substrate. Quantifications were done using 
GelDoc (Bio-Rad). 
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3.5 Immunocytochemistry 
 
PC6.3-cells in collagen-coated 24-well plates were fixed for 20 min RT using 4% 
paraformaldehyde (PFA), washed in phosphate-buffered saline (PBS) and permeabilized 
with 0,1% Triton-X-PBS for 5 min. After blocking with 5% BSA-PBS, the primary 
antibody for NFκB (p65) was added. The next day cells were incubated with Cy3-
conjugated secondary antibody and nuclei were stained using Hoechst 33258.  
 
 
3.6 PCR and Light cycler 
 
Total RNA was extracted and cDNA was synthesized from control and treated cells using 
dTT primers according to the manufacturers protocol (ThermoScript RT-PCR system). 
PCR was carried out by using the following primers: BDNF: FW 5’-TCG GTT GCA 
TGA AGG C-3’ and RV 5’-GGT TTT CTT CGT TGG GC-3’; IL-6: FW 5‘-CCA CCA 
GGA ACG AAA GT-3’ and RV 5’-GCA TCA TCG CTG TTC ATA C -3’; SOD1: FW 
5-CAA GCG GTG AAC CAG TTG TG-3 and RV 5’-TGA GGT CCT GCA GTG GTA 
C-3′; SOD2: FW 5‘-GCC TGC ACT GAA GTT CAA TG -3’ and RV 5’-ATC TGT 
AAG CGA CCT TGC TC -3’; TRX2: FW 5’-GGA CTT TCA TGC ACA GTG -3’ and 
RV 5’-CGT CCC CGT TCT TGA T -3’. XIAP: FW 5’-TGC TGG ACT CTA CTA CA -
3’ and RV 5’-GAC TTG ACT CAT CCT GCG A -3’; β-actin from the same cDNA 
samples was used to control the total cDNA levels with the following primers: FW 5′-
CAC ACT GTG CCC ATC TAT GA-3’ and RV 5’-CCA TCT CTT GCT CGA AGT 
CT-3’. To detect human XIAP from transfected cells, we used human specific primers: 
FW 5′-CCC AAA TTC AAC AAA TCT-3’ and RV 5-GAC TTG ACT CAT CTT GCA 
T-3’. Light Cycler was carried out for BDNF and actin by using the same primers as 
mentioned above. 
 
 
3.7 Luciferase Assay 
 
In luciferase assays cells were (co-)transfected with NFκB reporter or BDNF promoter 
I/IV constructs. Renilla luciferase (pRL-TK) was used to control transfection efficiency. 
In some experiments dominant negative (dn)-IκB plasmid was used to inhibit NFκB. 
Cells were lysed in lysis buffer containing 25mM Tris-phosphate (pH 7.8), 2mM DTT, 
2mM 1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid, 10% glycerol and 1% Triton 
X-100. For assaying the expression of Renilla and firefly luciferase we used the dual 
luciferase substrate and the activites were measured by luminometer (TD-20/20, 
Luminometer Turner Designs). The values for firefly luciferase were normalized to the 
Renilla luciferase activity.  
 
 
3.8 Statistics 
 
Paired t-test and one-way ANOVA were used for statistical comparisons of our 
experiments. 
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4. RESULTS AND DISCUSSION 
 
4.1 XIAP decreases the production of intracellular ROS levels and cell death 
after oxidative stress (I + supplementary data) 
 
The first aim was to study whether XIAP is able to have an effect on intracellular ROS 
levels, and cell death caused by ROS. It was noticed in our collaboration group using 
XIAP-TG mice that XIAP is able to protect against neuronal tissue loss after neonatal 
hypoxia-ischemia (Wang et al., 2004). There was also some evidence that XIAP might 
have an association with oxidative stress (Saito et al., 2004). We had a reason to believe 
that XIAP could reduce oxidative stress in our in vitro PC6.3-cell model as well, and we 
started to study this more closely. We used a construct with XIAP-EGFP fusion protein 
for transfections, so it was possible to count only the transfected, XIAP-overexpressing 
cells. DHE was used as an indicator to measure the amount of ROS, and the calculation 
of DHE-positive cells from GFP-positive cells was carry out by FACSAria. We observed 
that overexpression of XIAP reduces the generation of intracellular ROS in neuronal 
PC6.3-cells both alone and after exposure to oxidative stress by 100 µM xanthine (X) and 
200 mU/ml xanthine oxidase (XO) for 1 hour (I ; see also chapter 4.2.2, figure 10). 
Parallel results concerning XIAP and oxidative stress was observed in vivo XIAP-
transgenic (XIAP-TG) mice as well (Zhu et al., 2007). 
 
The second aim was to confirm that XIAP is able to reduce cell death caused by ROS. 
Because the mechanisms of ROS leading to cell death are not fully understood, we also 
wanted to examine if the cell death is apoptotic or non-apoptotic in our model. With the 
MTT assay we perceived that overexpression of XIAP reduces cell death caused by ROS 
(X 100µM + XO 100 mU/ml; for 24h) (I). Then we investigated with few other methods 
whether cell death caused by ROS is apoptotic or non-apoptotic. Spectrin and PARP 
antibodies were used in Western Blotting analysis for determination of calpain and 
caspase activation after treatment with X+XO. Calpain is known to be activated in 
several necrotic and apoptotic conditions while caspase-3 is activated only in neuronal 
apoptosis (Wang, 2000). Both of these are cysteine proteases, and it is known that 
cleavage of spectrin occurs if caspase-3 and/or calpain are activated. PARP is a substrate 
of caspase-3 so it is cleaved if caspase-3 is activated. Our results indicated that X+XO 
stimulation does not activate caspase-3, but it activates calpain (figure 7a). This was the 
first support for the hypothesis that cell death caused by ROS (X+XO) is not apoptotic, at 
least in PC6.3-cells. BAF was used to inhibit caspases, and with the MTT assay we 
analysed if BAF was able to protect cells against xanthine and xanthine oxidase (figure 
7b). Judging by it not having any protecting effects, X+XO must have other mechanisms 
besides caspases. This suggests support for the previous data that cell death caused by 
X+XO is not apoptotic.  Last but not least, Hoechst-staining was used for determination 
of DNA content in single cell nucleus, revealing that some of the nuclei of cells treated 
with X+XO were condensed (figure 7c). Some of the nuclei had started to disintegrate 
with a structure that did not seem to be apoptotic, but because nuclear chromatin 
condensation occurred as well, cell death did not look like clear necrosis either. Maybe 
necroptosis then, or something in between necrosis and necroptosis? It is well-known that 
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XIAP can inhibit apoptotic cell death, but all of these data suggests that XIAP can protect 
cells against non-apoptotic cell death caused by oxidative stress as well.  
 
 
Figure 7. Cell death in our system is non-apoptotic (unpublished, supplementary data).  
a) Cleavage of spectrin is visible if caspase-3 and/or calpain are activated, and cleavage 
of PARP occurs if caspase-3 is activated. 100 µM xanthine (X) and 50/100 mU/ml 
xanthine oxidase (XO) for 24h cleaved part of normal spectrin (240 kDa) to 145/150 kDa 
calpain product, but either 120 kDa caspase-3 product of normal spectrin or 89 kDa 
caspase-3 product of normal (116 kDa) PARP were not observable. 100 nM 
staurosporine (STS; 24h) was used as a positive control for activation of caspase-3 and 
calpain. b) Caspase inhibitor BAF was not able to inhibit cell death caused by 50/100 µM 
xanthine (X) and 50/100 mU/ml xanthine oxidase (XO). According to this, cell death 
caused by X+XO is not apoptotic. c) Hoechst staining showed that some of the cell nuclei 
treated with 100 µM xanthine (X) and 100 mU/ml xanthine oxidase (XO) o/n were 
condensed, but some have started to disintegrate. Scale bar = 10 µM. 
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4.2 XIAP increases mitochondrial antioxidant levels (I) 
 
Based on previous findings, we were wondering whether XIAP might alter the regulation 
of antioxidant genes as well, and our next purpose was to find out whether this could be 
the case. This had not been shown before, but we noticed first that overexpression of 
XIAP increases both mRNA and protein levels of mitochondrial antioxidant SOD2 in 
neuronal PC6.3-cells (I ; see also chapter 4.2.2, figure 10). Parallel results concerning 
XIAP and intracellular antioxidants were published just a moment after our observations 
(Resch et al., 2008). Contrary to Resch and coworkers, we noticed that XIAP had no 
effect on the levels of SOD1 and catalase (I). Certainly, it has to be considered that they 
used XIAP -/- cells in their studies, and we used cells with overexpression of XIAP. In 
MEF-cells we also found out that overexpression of XIAP increased the protein levels of 
TRX2 (I). Our results indicated a preferential influence of XIAP particularly on the 
mitochondrial antioxidants: SOD2 and TRX2.  
 
4.2.1 XIAP activates NFκB (I, II, Supplementary data) 
Our next aim was to identify the mechanism behind the ability of XIAP to regulate SOD2 
and TRX2. Previous investigations had shown that XIAP is able to affect various 
signalling pathways, including NFκB activity in endothelial cells (Hofer-Warbinek et al., 
2000). In neuronal cells there was less evidence concerning the capability of XIAP to 
activate NFκB, but it was known that in neurons NFκB signalling is mainly protective 
(Middleton et al., 2000). We wondered whether XIAP would have an effect on the 
activation level of NFκB in neuronal cells as well, and studied this with three different 
methods in PC6.3-cells transfected with XIAP-constructs for 48 hours.  The conclusion 
with all these methods was that overexpression of XIAP increases activation of NFκB 
(table 4, figure 8; see also chapter 4.2.2, figure 10).  In addition to these, findings with 
PC6.3-cells, we also we noticed that overexpression of XIAP increases the activation of 
NFκB in E17 HC neurons as well (figure 8B).  
 
 
 
Table 4. Overexpression of XIAP increases the activation of NFκB. 
Method How it was seen that XIAP activates NFκB? 
Western Blotting Protein IκBα was phosphorylated in XIAP transfected cells 
Immunocytochemistry 
Protein p65 was mainly in the nucleus in  
XIAP transfected cells 
  Depending on the transfection efficiency, the  
NFκB Luciferase Reporter Assay activity of NFκB was about 10-20 times higher in 
  XIAP-transfected cells compared to control cells  
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Figure 8. Overexpression of XIAP increases the activation of NFκB both in neuron-like 
PC6.3-cells and in E17 HC neurons. Cells were transfected with NFκB-Luciferase 
reporter plasmid together with control pcDNA3.1 (C) or XIAP-myc (XIAP) expression 
plasmid. Cotransfection with Renilla expression vector was used as a control to assay 
transfection efficiency. Results are fold induction of LUC activity after a) 24 and 48 h 
(PC6.3) and b) 7 days (E17 HC neurons) of transfection (unpublished, supplementary 
data). 
 
 
Interaction between BIR1 domain of XIAP and TAB1 is known to be crucial for XIAP-
induced activation of NFκB through TAK1 (Lu et al., 2007). The N-terminal domain of 
TAB1 interacts with the TAK1 kinase domain (figure 9). Activation of TAK1 on the 
other hand leads to phosphorylation of IKK and activation of NFκB (Wang et al., 1998). 
Researchers have shown that both activation of NFκB (or its Drosophila homologue 
Relish) and XIAP lead to inhibition of JNK signalling through proteasomal degradation 
of TAK1 (Park et al., 2004, Kaur et al., 2005). Prolonged activation of JNK is ROS-
dependent, which supports the capability of XIAP, through NFκB, to reduce oxidative 
stress and perhaps modulate the expression of intracellular antioxidants. It would be 
interesting to investigate the roles of TAK1 and TAB1 in our model more closely in the 
future because it is known that XIAP activates NFκB through TAB1 and TAK1 (Lu et 
al., 2007). 
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Figure 9. A schematic model for XIAP-mediated activation of NFκB. The BIR1 domain 
of XIAP is crucial for NFκB activation through TAB1 and TAK1. Activation of NFκB 
itself can induce degradation of TAK1 via upregulation of downstream target genes, such 
as XIAP. The RING domain of XIAP mediates the polyubiquitination of TAK1 and 
proteosomal degradation. Degradation of TAK1 leads to inhibition of JNK pathway.  
 
 
4.2.2 The effect of XIAP on the levels of SOD2 and TRX2 is NFκB-dependent      
(I, III) 
 
NFκB is known to have a role in SOD2 induction: p65 is capable of mediating the 
TNFα-induced SOD2 increase, and Heat-Shock Protein 25 (HSP25) regulates SOD2 
through activation of NFκB (Maehara et al., 2000, Yi et al., 2002, Guo et al., 2003). We 
started to study if the effect of XIAP on SOD2 was mediated by NFκB, and first blocked 
the activity of NFκB with 2,5 mM ASA. Overexpression of XIAP did not increase the 
level of SOD2 if ASA was present (I), but because ASA can affect so many other cell 
signalling cascades as well, we wanted to confirm the observation with some other 
method as well. Secondly, we studied the same thing in immortalized embryonic 
fibroblast cell lines (1 and 2) from NFκB RelA/p65 knockout (KO) mice, which have 
been also used in earlier publications to study the NFκB pathway (Beg and Baltimore, 
1996, Farhana et al., 2005). We observed in both of the p65-/- cell lines that the rise of 
SOD2 is p65-dependent: overexpression of XIAP was not able to increase the protein 
levels of SOD2 in cells lacking p65 (-/-), but the increase was visible in control fibloblast 
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cell line 3T3 (I). This data suggests that NFκB is involved in the ability of XIAP to 
increase SOD2 (figure 10).  
 
We also investigated whether the increase of mitochondrial antioxidant protein TRX2 by 
XIAP is NFκB dependent. Earlier, it has been shown that TRX2 inhibits TNFα-induced 
ROS generation, downstream NFκB activation and apoptosis (Hansen et al., 2006). We 
noticed that overexpression of XIAP increased the amount of TRX2 in control 3T3-cells 
but not in p65-/- cell lines (I), so NFκB is involved in this effect of XIAP (figure 10).  
 
One more thing we noticed was that the basic levels of SOD2 and TRX2 are lower in 
cells lacking p65 than in control cells (III). This observation concerned only these 
mitochondrial antioxidants, and e.g. SOD1 was not increased by XIAP (I), and the 
amount of it was not lower in p65-/- cell lines (data not shown). Actually the protein 
levels of SOD1 seemed to be approximately higher in p65-/- cell lines than in control 3T3 
cell line. This brings to mind whether this could be some kind of a compensatory 
mechanism of the p65-/- cells?  
 
 
 
Figure 10. Summarizing figure: XIAP reduces oxidative stress and increases the levels of 
mitochondrial antioxidants (SOD2 and TRX2) through increased activation of NFκB. 
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4.3 XIAP increases the amount of BDNF and induces BDNF gene activation 
through NFκB (II) 
 
Using Affymetrix microarrays to analyse gene expression, our collaborator group had 
observed that the mRNA of neurotrophic factor BDNF was upregulated in brain tissue of 
transgenic (TG) XIAP mice with overexpression of XIAP in neurons. With Western 
Blotting analysis we noticed that the protein levels of BDNF were also higher in the 
brains of XIAP-TG mice than in control brains (II). The connection of XIAP and BDNF 
had not been observed before, but the inhibition of XIAP activity has been shown to 
prevent GDNF-mediated neuroprotective effects (Perrelet et al., 2002). 
 
Our next purpose was to study the mechanisms behind the effect of XIAP on BDNF by 
using E17 HC neurons. First, we confirmed that we are able to see the same effect of 
XIAP to BDNF in vitro as well, and noticed that overexpression of XIAP (2-7 days) 
increased both mRNA and protein levels of BDNF in E17 HC neurons (II). We also made 
a notification that in the presence of XIAP-antagonist embelin, XIAP-myc transfection 
did not affect to BDNF. Experiments made with neurons treated with XIAP silencing 
RNA (siRNA) show that both mature BDNF and its precursor pro-BDNF were 
downregulated when XIAP was silenced (II). This indicates that XIAP is able to affect 
BNDF already in its synthesis phase.   
 
Then, we investigated the gene activity of BDNF by using BDNF promoters linked to 
luciferase reporter in neuronal PC6.3-cells. Our observation was that both BDNF 
promoter I and IV activities were increased if XIAP was overexpressed (II). In contrast to 
this, downregulation of XIAP with siRNA decreased BDNF I and IV promoter activities 
(II). dn-IκB construct almost blocked the XIAP increased activation of BDNF promoter 
IV, and reduced the increase of promoter I activity (II). This indicates that NFκB 
activation induced by XIAP affects transcription of promoters I and IV BDNF. Previous 
studies have shown the presence of a binding site for NFκB in the BDNF promoter IV, 
that mediates the stimulation of BDNF induced by N-methyl-d-aspartate receptor 
(NMDAR) (Jiang et al., 2008). NFκB-binding element has also been identified in the 
BDNF promoter I which is involved in the regulation of BDNF expression by kainic acid 
(KA) (Lubin et al., 2007). These binding sites may be targets for the NFκB-dependent 
regulation of the BDNF gene activity by XIAP as well. 
 
 
4.3.1 Other proteins involved in the regulation of BDNF by XIAP 
 
We also desired to examine if BDNF was regulated through other proteins induced by 
XIAP. It was known that XIAP is able to regulate interleukin-6 (IL-6), at least in 
endothelial cells, via stimulation of NFκB and MAP kinase signalling pathways (Resch et 
al., 2006). IL-6 has been connected to neuroprotection and neuronal survival after 
ischemic and other injuries (Ohtaki et al., 2006, Fritzenwanger et al., 2007). However, 
not much was known about the protective genes affected by cytokines in the brain. We 
clarified that XIAP does this in neuronal PC6.3-cells and in E17 HC neurons as well (II). 
We also studied if IL-6 was associated with the ability of XIAP to regulate BDNF and 
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NFκB signalling. Our observation was that IL-6 increased the protein levels of BDNF in 
E17 HC neurons, and IL-6 antibodies blocked the upregulation of BDNF caused by XIAP 
(II). Anyhow, IL-6 did not alter the activation of BDNF Promoter activities, as XIAP 
itself did (II). Altogether, IL-6 is related to interconnection of XIAP and BDNF, but the 
precise mechanism behind this remains to be studied in the future. It also would be worth 
to clarify whether XIAP would increase IL-6 if NFκB was blocked - at least XIAP was 
not able to activate BDNF promoters I and IV completely if dn-IκB was present.  
 
Using Affymetrix microarrays, our collaborator group also noticed that the expression of 
BDNF receptor TrkB was increased in the XIAP overexpressing neurons in TG-XIAP 
mice compared to controls. We observed the same elevation of TrkB by Western Blotting 
analysis in XIAP-transfected E17 HC neurons compared to control cells (II). The exact 
mechanism by which XIAP increases TrkB here and whether it involves NFκB, remains 
to be studied. We also studied the levels of activated (phosphorylated) TrkB receptors in 
E17 HC neurons using p-TrkA/B antibodies. Only a small amount of TrkA is found in 
HC neurons, so the results can be considered as indicators of TrkB activation. 
Overexpression of XIAP increased the levels of p-TrkB in E17 HC neurons (II), which 
suggests that the whole BDNF-TrkB-system is more activated in XIAP-overexpressing 
neurons. Following the phosphorylation of TrkB, BDNF can stimulate various signalling 
cascades which regulates transcription factors such as the CREB protein (Huang and 
Reichardt, 2003). Activation (phosphorylation) of CREB on the other hand is known to 
regulate the transcription of other genes including BDNF, and CREB is usually related to 
same pathological conditions as BDNF. We also noticed that the levels of phosphorylated 
CREB protein (p-CREB) were increased in HC neurons after the XIAP overexpression 
(II). Presence of BDNF scavenging TrkB-soluble receptor bodies (TrkB/Fc chimeras) 
prevented the increase of p-TrkB and p-CREB induced by XIAP-transfection, which 
suggests that our findings are originating from the increased level of BDNF caused by 
overexpression of XIAP. 
 
Altogether, these studies show that XIAP has an influence on the expression of the 
neurotrophic molecules BDNF and IL-6. XIAP affects neuronal signalling via the 
upregulation of p-TrkB and p-CREB. Our results expose a novel cytokine network in the 
brain, which involves XIAP, BDNF, and IL6 interconnected through the NFκB system 
(figure 11), which can influence several aspects of neuronal survival. Because BDNF has 
a role in diseases where oxidative stress is also involved, such as Huntington’s Disease, it 
is really fascinating that XIAP can have a positive effect on both BDNF signalling and 
oxidative stress.  
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Figure 11. Summarizing figure: XIAP affects BDNF levels and gene activation through 
NFκB. The levels of IL-6 are also increased by XIAP, and NFκB is known to have a role 
in the interconnection of XIAP and IL-6 (Resch et al., 2006). IL-6 seems to be somehow 
involved in interconnection of XIAP and BDNF as well, while it increases the amount of 
BDNF. In addition, XIAP increases the activation of BDNF-TrkB-system and CREB. 
 
4.4 Oxidative stress is involved in HD (III) 
 
Changes in mitochondria and other organelles with increased oxidative stress have been 
linked to HD (Gil and Rego, 2008, Lipinski and Yuan, 2004). Our own group has 
previously shown that N-terminal huntingtin proteins with extended polyQ repeats induce 
ER stress (Reijonen et al., 2008). On the other hand, ER is able to produce ROS during 
normal cell functions, such as metabolism and protein folding (Finkel and Holbrook, 
2000, Jones, 2008). In addition to ROS, some transcription factors or their co-activators 
which have been connected to stress reactions, such as CREB, NFκB, PGC1α, and p53, 
have been noticed to be affected by CAG expansion (Steffan et al., 2000, Roze et al., 
2008, Cui et al., 2006, Weydt et al., 2006). In our own studies, we had previously 
connected NFκB to oxidative stress and intracellular antioxidants, which raised the 
question, that maybe oxidative stress together with NFκB may have a role in HD? 
 
The target of this part of the study was to investigate oxidative stress, intracellular 
antioxidants and NFκB in our in vitro model of HD. We observed in PC6.3-cells 
transfected with expression plasmids encoding different polyQ repeats of huntingtin 
exon-1, that the amount of ROS increases while the number of CAG-repeats expands (III; 
figure 12). Cells transfected with the construct containing 18 polyQ ("normal amount") 
repeats show about the same ROS levels as control cells, while ROS levels of cells 
transfected with the mutant, 120 polyQ repeats containing construct were about threefold 
higher. DHE was used as an indicator to measure the amount of ROS, and the calculation 
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of DHE-positive cells from GFP-positive cells was carried out by FACSAria. The protein 
levels of intracellular antioxidants SOD2, SOD1, TRX2, and catalase decreased in cells 
expressing mutant N-terminal fragment huntingtin proteins compared to control cells as 
measured with Western Blotting analysis (III; figure 12). The same decrease was visible 
for the protein levels of NFκB as well. NFκB activation was quantified with the NFκB 
reporter (luciferase) assay, and the activation of NFκB was about half in cells transfected 
with disease-including 75 Q-containing huntingtin compared to cells transfected with 
“normal” amount (17 Q) containing huntingtin (III). In the previous studies we noticed 
that at least mitochondrial antioxidants were increased by XIAP through NFκB, and the 
amount of ROS were decreased by XIAP. It would be worth finding out whether the 
induction of NFκB activity e.g. by XIAP inhibits the accumulation of ROS and/or 
reduction of antioxidant levels caused by mutant huntingtin? Reduced XIAP levels have 
been linked to HD both in brain-derived cells expressing mutant huntingtin, and in post-
mortem HD brain tissue (Goffredo et al., 2005). And although XIAP would not be 
affected directly in HD or vice versa, it is certainly possible that modulation of XIAP can 
vicariously have positive effects in HD by reducing oxidative stress, and in this way 
protecting cells.  
 
 
Figure 12. Summarizing figure: the amount of ROS increases, and intracellular 
antioxidants (i.e. SOD2 and TRX2) and NFκB decreases, while the number of CAG-
repeats multiplies. Broken lines present the data according to the previous studies: XIAP 
reduces oxidative stress and increases the amount of SOD2 and TRX2, and activation of 
NFκB. 
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4.5 RSV pretreatment reduces the production of intracellular ROS levels and 
cell death after oxidative stress (IV) 
 
Previously, RSV has been shown to increase antioxidant levels in cultured PC12 cells and 
SOD2 in human fibroblasts (Chen et al., 2005, Robb et al., 2008). RSV has also shown to 
have neuroprotective effects against metabolic dysfunction induced by mutant huntingtin 
(Parker et al., 2005). Based on the antioxidant properties of RSV, we started to 
investigate the mechanisms more closely. First we confirmed that RSV pretreatment is 
able to reduce oxidative stress also in our system. We pretreated neuronal PC6.3-cells 
with 50 or 75 µM RSV, and 30 min after that stimulated cells with 100 µM xanthine (X) 
and 200 mU/ml xanthine oxidase (XO) for 1 hour. We noticed that RSV reduced 
generation of intracellular ROS both alone and after exposure to oxidative stress (figure 
13). DHE was used as an indicator to measure the amount of ROS, and the calculation of 
DHE-positive cells was carried out by FACSAria. We also examined cell viability with 
the MTT assay following 24 h X + XO (100 µM + 200 mU/ml) treatment, and found that 
both RSV concentrations (50 µM and 75 µM) reduced cell death caused by X + XO 
about 25 %.  
 
 
4.5.1 RSV increases mitochondrial antioxidants and XIAP, and NFκB may 
contribute to this (IV) 
   
Because RSV decreased the levels of ROS in neuron-like PC6.3-cells, we had a reason to 
believe that RSV may have an influence on intracellular antioxidants as well. Earlier, it 
has been shown that RSV can induce SOD2 in human fibroblasts (Robb et al., 2008). We 
noticed that RSV-treatment (50-75 µM; 24 h) increases mRNA and protein levels of 
mitochondrial antioxidants SOD2 and TRX2, in neuronal PC6.3-cells (IV; figure 13). 
The increase was even higher if xanthine and xanthine oxidase were added. We also 
investigated if RSV is able to influence XIAP levels, and observed, that RSV increased 
both mRNA and protein levels of it (IV; figure 13). After a longer treatment (72 h), the 
effect of RSV on SOD2 and TRX2 was even stronger, and visible already with smaller 
concentrations (10 µM and 25 µM). 
 
Many of the antioxidants are known to be regulated by the NFκB system. We have 
noticed in our previous studies that the responses of SOD2 and TRX2 to XIAP are 
mediated by NFκB activation (I). Because of this, we were considering if the effects of 
RSV on mitochondrial antioxidants are mediated by NFκB as well? It has been reported 
that RSV suppresses NFκB e.g. in carcinoma cells (Manna et al., 2000, Banerjee et al., 
2002). Anyway, the connection of RSV and NFκB has not been studied that much in 
neuronal cells. It is still known that RSV can act differently in different cell types 
(Shakibaei et al., 2009). The same RSV concentration can be protective to some cells and 
harmful to others, and high concentrations may induce apoptosis whereas low 
concentrations may promote cell survival (Jang et al., 1997, In et al., 2006, Shakibaei et 
al., 2009). The precise timing for RSV treatment is also worth to consider.  
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The NFκB Luciferase Reporter Assay showed that after 24 h, 50 µM RSV had a small 
positive effect on the activity of NFκB, but 75 µM RSV did not (IV). After 48 h, both 50 
µM and 75 µM RSV increased the activity of NFκB about 2.5 fold. It is possible that the 
activation of NFκB is involved in the increase of antioxidants mediated by RSV (figure 
12). Apart from NFκB, other signalling pathways may be involved in counteracting 
oxidative stress. It has been shown that RSV can activate AMPK, SIRT-1, and PGC-
1α (Baur et al., 2006, Lagouge et al., 2006). It remains to be studied whether some of 
these pathways are affected by RSV in PC6.3-cells. PGC-1α has previously been linked 
to intracellular antioxidant proteins, and has shown to be regulated by RSV (St-Pierre et 
al., 2006, Lagouge et al., 2006). 
 
Altogether, our observations present that RSV protects neuron-like PC6.3-cells from cell 
death caused by oxidative stress, and RSV reduces the generation of intracellular ROS. 
The NFκB signalling pathway may be involved in this. RSV is worth to consider as a 
drug candidate because it is known to cross the blood-brain barrier (BBB), and increased 
ROS levels are presented to be involved in neurodegenerative diseases such as 
Huntington’s, Parkinson’s, and Alzheimer’s diseases(Barnham et al., 2004, Henrotin et 
al., 2003, Rego and Oliveira, 2003, Baur and Sinclair, 2006). Certainly the clinical use of 
RSV will need careful analysis of its kinetics, actions and pharmacological and 
toxicological profiles.  
 
 
 
Figure 13. Summarizing figure: RSV decreases the amount of ROS, and increases the 
mitochondrial antioxidants (SOD2 and TRX2) and XIAP. RSV is also able to activate 
NFκB if the dose and timing are optimal. SOD2, TRX2 and XIAP are downstream target 
genes of NFκB, so it is possible that the activation of NFκB is involved in the increase of 
antioxidants mediated by RSV as well.  
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5. CONCLUSIONS AND FUTURE POSSIBILITIES 
 
The first aim of this work was to clarify the possible role and mechanisms of anti-
apoptotic protein XIAP in cell death caused by oxidative stress in neuronal cells. We 
observed that XIAP reduces oxidative stress and cell death caused by ROS in neuronal 
cells. Because oxidative stress is the result of an imbalance between pro- and antioxidant 
homeostasis, we had reason to believe that XIAP might alter the regulation of antioxidant 
genes in neuronal cells as well. This had not been shown before, and our next purpose 
was to clarify whether XIAP has this effect?  
 
Secondly, we showed that XIAP activates NFκB in neuronal cells, and increases both 
mitochondrial antioxidants (SOD2 and TRX2) and BDNF signalling through NFκB.  
Because it is known that XIAP activates NFκB through TAB1 and TAK1, it would be 
interesting to investigate the roles of TAK1 and TAB1 in our model more closely in the 
future. Modulation of XIAP is also an interesting possibility to consider in various 
therapies to reduce cell injuries caused by increased oxidative stress. 
   
Thirdly, we saw in the in vitro HD model that the amount of ROS increases while the 
number of CAG-repeats expands. The protein levels of intracellular antioxidants (SOD1, 
SOD2, TRX2, and catalase) and NFκB also decreased in cells expressing mutant 
huntingtin compared to control cells. These results support that in HD there is an 
imbalance between pro- and antioxidant homeostasis within the cells. Because NFκB also 
seemed to be involved, what naturally came to mind was: would it be possible to affect 
HD in a positive way by modulating XIAP? XIAP not only decreases oxidative stress, 
but it also regulates BDNF signalling through NFκB, and deprivations in BDNF gene 
transcription has been demonstrated to be in connection with the mutation in the HD gene 
as well. The role of XIAP in our HD cell model remains to be studied closely in the 
future. 
 
Lastly, we studied whether RSV is able to protect neuronal cells against oxidative stress, 
and noticed that it reduces oxidative stress and cell death caused by ROS. RSV also 
increased the amount of mitochondrial antioxidants (SOD2 and TRX2) and XIAP. This 
effect was even stronger if the treatment was longer. We also observed that RSV is able 
to activate NFκB if the dose and timing are optimal. Because RSV is known to cross the 
blood-brain barrier, it would be an interesting compound to examine as a drug candidate 
in disorders where oxidative stress is involved. Certainly, the clinical use of it will need a 
lot of studies to analyse the kinetics, actions and pharmacological and toxicological 
profile of it. 
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